Vertex’s ‘Slow Train To Pain’ R&D Rolls On

VX-548 Moves To Phase II

 
• By Sten Stovall
  
VX-548 is the most recent of Vertex's channel-blocking agents to enter the clinic • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D